Literature DB >> 24879459

Differences in dynamic susceptibility contrast MR perfusion maps generated by different methods implemented in commercial software.

Laura Orsingher1, Silvia Piccinini, Girolamo Crisi.   

Abstract

PURPOSE: There are several potential sources of difference that can influence the reproducibility of magnetic resonance (MR) perfusion values. We aimed to investigate the reproducibility and variability of dynamic susceptibility contrast (DSC) MR imaging (MRI) parameters obtained from identical source data by using 2 commercially available software applications with different postprocessing algorithms. METHODS AND MATERIALS: We retrospectively evaluated DSC-MRI data sets of 24 consecutive patients with glioblastoma multiforme. Perfusion data were postprocessed with 2 commercial software packages, NordicICE (NordicNeuroLab, Bergen, Norway) and GE Brainstat (GE Healthcare, Milwaukee, Wis), each of which offers the possibility of different algorithms. We focused the comparison on their main analysis issues, that is, the gamma-variate fitting function (GVF) and the arterial input function (AIF). Two regions of interest were placed on maps of perfusion parameters (cerebral blood volume [CBV], cerebral blood flow [CBF], mean transit time [MTT]): one around tumor hot spot and one in the contralateral normal brain. A one-way repeated-measures analysis of variance was conducted to determine whether there was a significant difference in the calculated MTT, CBV, and CBF values.
RESULTS: As regards NordicICE software application, the use of AIF is significant (P = 0.048) but not the use of GVF (P = 0.803) for CBV values. Additionally, in GE, the calculation method discloses a statistical effect on data. Comparing similar GE-NordicICE algorithms, both method (P = 0.005) and software (P < 0.0001) have a statistical effect in the difference. Leakage-corrected and uncorrected normalized CBV (nCBV) values are statistically equal. No statistical differences have been found in nMTT values when directly calculated. Values of nCBF are affected by the use of GVF.
CONCLUSION: The use of a different software application determines different results, even if the algorithms seem to be the same. The introduction of AIF in the data postprocessing determines a higher estimates variability that can make interhospital and intrahospital examinations not completely comparable. A simpler approach based on raw curve analysis produces more stable results.

Entities:  

Mesh:

Year:  2014        PMID: 24879459     DOI: 10.1097/RCT.0000000000000115

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  10 in total

1.  Heterogeneous Optimization Framework: Reproducible Preprocessing of Multi-Spectral Clinical MRI for Neuro-Oncology Imaging Research.

Authors:  Mikhail Milchenko; Abraham Z Snyder; Pamela LaMontagne; Joshua S Shimony; Tammie L Benzinger; Sarah Jost Fouke; Daniel S Marcus
Journal:  Neuroinformatics       Date:  2016-07

2.  Multisite Concordance of DSC-MRI Analysis for Brain Tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project.

Authors:  K M Schmainda; M A Prah; S D Rand; Y Liu; B Logan; M Muzi; S D Rane; X Da; Y-F Yen; J Kalpathy-Cramer; T L Chenevert; B Hoff; B Ross; Y Cao; M P Aryal; B Erickson; P Korfiatis; T Dondlinger; L Bell; L Hu; P E Kinahan; C C Quarles
Journal:  AJNR Am J Neuroradiol       Date:  2018-05-24       Impact factor: 3.825

3.  Reproducibility of dynamic contrast-enhanced MRI and dynamic susceptibility contrast MRI in the study of brain gliomas: a comparison of data obtained using different commercial software.

Authors:  Gian Marco Conte; Antonella Castellano; Luisa Altabella; Antonella Iadanza; Marcello Cadioli; Andrea Falini; Nicoletta Anzalone
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

Review 4.  Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours.

Authors:  Ananya Chakravorty; Timothy Steel; Joga Chaganti
Journal:  Neuroradiol J       Date:  2015-10-16

5.  Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.

Authors:  Reena P Thomas; Seema Nagpal; Michael Iv; Scott G Soltys; Sophie Bertrand; Judith S Pelpola; Robyn Ball; Jaden Yang; Vandana Sundaram; Jonathan Lavezo; Donald Born; Hannes Vogel; J Martin Brown; Lawrence D Recht
Journal:  Clin Cancer Res       Date:  2019-09-19       Impact factor: 12.531

6.  Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression.

Authors:  Zachary S Kelm; Panagiotis D Korfiatis; Ravi K Lingineni; John R Daniels; Jan C Buckner; Daniel H Lachance; Ian F Parney; Rickey E Carter; Bradley J Erickson
Journal:  J Med Imaging (Bellingham)       Date:  2015-05-26

7.  Standardized acquisition and post-processing of dynamic susceptibility contrast perfusion in patients with brain tumors, cerebrovascular disease and dementia: comparability of post-processing software.

Authors:  Manuel Alexander Schmidt; Michael Knott; Philip Hoelter; Tobias Engelhorn; Elna Marie Larsson; Than Nguyen; Marco Essig; Arnd Doerfler
Journal:  Br J Radiol       Date:  2019-10-24       Impact factor: 3.039

Review 8.  MRI biomarkers in neuro-oncology.

Authors:  Marion Smits
Journal:  Nat Rev Neurol       Date:  2021-06-20       Impact factor: 42.937

Review 9.  Radiohistogenomics of pediatric low-grade neuroepithelial tumors.

Authors:  Asim K Bag; Jason Chiang; Zoltan Patay
Journal:  Neuroradiology       Date:  2021-03-29       Impact factor: 2.804

10.  Dynamic Susceptibility Contrast-MRI Quantification Software Tool: Development and Evaluation.

Authors:  Panagiotis Korfiatis; Timothy L Kline; Zachary S Kelm; Rickey E Carter; Leland S Hu; Bradley J Erickson
Journal:  Tomography       Date:  2016-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.